(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 May 2023 (19.05.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/084094 A1

(51) International Patent Classification:
A61K 39/12 (2006.01)

(21) International Application Number:
PCT/EP2022/081839

(22) International Filing Date:
14 November 2022 (14.11.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

21306581.6	15 November 2021 (15.11.2021)	EP
63/279,945	16 November 2021 (16.11.2021)	US
22306119.3	27 July 2022 (27.07.2022)	EP

(71) Applicants: **THERAVECTYS** [FR/FR]; Bat Pasteur Biotop, 28 rue du Docteur Roux, 75015 PARIS (FR). **INSTITUT PASTEUR** [FR/FR]; 25-28 rue du Docteur Roux, 75015 PARIS (FR).

(72) Inventors: **CHARNEAU, Pierre**; 25-28 rue du Docteur Roux, 75015 PARIS (FR). **ANNA, François**; Bâtiment Pasteur Biotop, 28 rue du Docteur Roux, 75015 PARIS (FR). **MONCOQ, Fanny**; Bâtiment Pasteur Biotop, 28 rue du Docteur Roux, 75015 PARIS (FR). **NOIRAT, Amandine**; Bâtiment Pasteur Biotop, 28 rue du Docteur Roux, 75015 PARIS (FR). **MAJLESSI, Laleh**; 25-28 rue du Docteur Roux, 75015 PARIS (FR). **DOUGUET, Laetitia**; Bâtiment Pasteur Biotop, 28 rue du Docteur Roux, 75015 PARIS (FR). **FERT, Ingrid**; Bâtiment Pasteur Biotop, 28 rue du Docteur Roux, 75015 PARIS (FR).

(74) Agent: **CABINET NONY**; 11 rue Saint-Georges, 75009 PARIS (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

WO 2023/084094 A1

(54) **Title:** LENTIVIRAL VECTORS FOR EXPRESSION OF HUMAN PAPILLOMAVIRUS (HPV) ANTIGENS AND ITS IMPLEMENTATION IN THE TREATMENT OF HPV INDUCED CANCERS

(57) **Abstract:** The present invention relates to a lentiviral vector, in particular a non-integrative lentiviral vector, comprising at least four distinct nucleic acid sequences encoding HPV antigens, to a lentiviral vector particle comprising said vector, to an isolated cell comprising the same, and to a vaccine composition comprising the said lentiviral vector, lentiviral vector particle or cell. The present invention further relates to their implementation in the treatment or prevention of an HPV induced cancer.